Undetectable Preoperative Levels of Serum CA 19-9 Correlate with Improved Survival for Patients with Resectable Pancreatic Adenocarcinoma
- 1 July 2004
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 11 (7) , 644-649
- https://doi.org/10.1245/aso.2004.11.025
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Decrease of CA 19–9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancerBritish Journal of Cancer, 2000
- CA 19-9 in Pancreatic CancerSurgical Oncology Clinics of North America, 1998
- Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreasAnnals of Surgical Oncology, 1997
- CA 19‐9 as a prognostic index after resection for pancreatic cancerJournal of Surgical Oncology, 1993
- Prognostic Value of Serum CA 19–9 Levels in Pancreatic AdenocarcinomaAnnals of Surgery, 1992
- Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotypeBritish Journal of Cancer, 1991
- CA 19-9 and pancreatic adenocarcinomaCancer, 1986
- Normal Salivary Mucin Contains the Gastrointestinal Cancer‐Associated Antigen Detected by Monoclonal Antibody 19–9 in the Serum Mucin of Patients1Vox Sanguinis, 1985
- LEWIS BLOOD-TYPE MAY AFFECT THE INCIDENCE OF GASTROINTESTINAL CANCERThe Lancet, 1982
- Colorectal carcinoma antigens detected by hybridoma antibodiesSomatic Cell and Molecular Genetics, 1979